Serp-1 for the Treatment of Acute Coronary Syndrome
Launched by VIRON THERAPEUTICS INC · Oct 19, 2005
Trial Information
Current as of July 05, 2025
Terminated
Keywords
ClinConnect Summary
A total of 72 subjects will be enrolled, separated into 3 dose groups and centrally randomized in a 3:1 ratio of Serp-1 injection to placebo control.Subjects will receive Serp-1 by intravenous (IV) bolus injection daily for 3 days, at dose levels of 5.0, 15, and 50 ug/kg/dose or placebo (0.9% normal saline) added to any prescribed therapy for ACS. Serp-1 will be administered as a single IV bolus injection. The initial IV bolus dose is administered immediately preceding the PCI procedure with subsequent doses administered 24 and 48 hours later.Subjects will be evaluated for adverse events, s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Established diagnosis of unstable angina or NSTEMI with one or more episodes of angina in the 24 hours before hospital admission
- • Scheduled for PCI
- Exclusion Criteria:
- • CABG within 6 months
- • Acute ST elevation, eligible for thrombolysis on initial examination
- • Coronary lesions with total thrombotic occlusions
- • Current immunosuppressant therapy
About Viron Therapeutics Inc
Viron Therapeutics Inc. is a biopharmaceutical company dedicated to advancing innovative therapeutic solutions for patients with challenging medical conditions. With a focus on developing novel treatments through cutting-edge research and robust clinical trials, Viron Therapeutics leverages its expertise in drug discovery and development to address unmet needs in various therapeutic areas. The company's commitment to scientific excellence and patient-centric approaches positions it at the forefront of the biopharmaceutical industry, striving to improve health outcomes and enhance the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Gainesville, Florida, United States
Ottawa, Ontario, Canada
Montreal, Quebec, Canada
Grand Rapids, Michigan, United States
Vicotria, British Columbia, Canada
Calgary, Ontario, Canada
London, Ontario, Canada
Patients applied
Trial Officials
Alexandra Lucas, MD
Study Director
Chief Clinical Officer- Viron Therapeutics
Jean-Claude Tardif, MD
Study Chair
Director- Montreal Heart Institute Research Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials